Comparison of two new HTLV-I/II screening methods, Abbott Alinity i rHTLV-I/II and Diasorin LIAISON® XL murex recHTLV-I/II, to Abbott Architect rHTLVI/II assay - Sorbonne Université Access content directly
Journal Articles Journal of Clinical Virology Year : 2023

Comparison of two new HTLV-I/II screening methods, Abbott Alinity i rHTLV-I/II and Diasorin LIAISON® XL murex recHTLV-I/II, to Abbott Architect rHTLVI/II assay

Abstract

Background: Diagnosis of Human T-cell Lymphotropic Virus (HTLV) types I and II infection requires sequencial testing with firstly a screening using an Enzyme immunoassay followed by a confirmatory test. Objectives: To compare the performances of the Alinity i rHTLV-I/II (Abbott®) and LIAISON® XL murex recHTLV-I/II serological screening tests to the ARCHITECT rHTLVI/II test followed if positive by HTLV BLOT 2.4, MP Diagnostics as the reference. Study design: 119 serum samples from 92 known HTLV-I infected patients and 184 from uninfected patients with HTLV were analyzed in parallel with, Alinity i rHTLV-I/II, LIAISON® XL murex recHTLV-I/II and ARCHITECT rHTLVI/II. Results: Alinity i rHTLV-I/II and Liaison XL murex recHTLV-I/II exhibited a total agreement with ARCHITECT rHTLVI/II for both positive and negative samples. Both tests are suitable alternatives for HTLV screening.
Fichier principal
Vignette du fichier
HTLV-HAL.pdf (806.49 Ko) Télécharger le fichier
Origin : Files produced by the author(s)

Dates and versions

hal-04086828 , version 1 (17-05-2023)

Identifiers

Cite

Vincent Guiraud, Florian Crémoux, Isabelle Leroy, Julien Cohier, Pierre Hernandez, et al.. Comparison of two new HTLV-I/II screening methods, Abbott Alinity i rHTLV-I/II and Diasorin LIAISON® XL murex recHTLV-I/II, to Abbott Architect rHTLVI/II assay. Journal of Clinical Virology, 2023, pp.105446. ⟨10.1016/j.jcv.2023.105446⟩. ⟨hal-04086828⟩
20 View
44 Download

Altmetric

Share

Gmail Facebook X LinkedIn More